Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Vol. 17, 04 December 2023
* Author to whom correspondence should be addressed.
Cancer is an important cause of human death in the world today. Traditional cancer treatment methods have many defects, such as high damage to normal cells and the inability to efficiently remove tumor cells. In recent years, due to the EPR effect of nano-targeted drugs can stay in the tumor site for a long time, as well as their high specificity to cancer cells and better therapeutic ability than traditional drugs, more and more scholars believe that nano-targeted drug delivery system is a very promising research direction for cancer treatment. This article focuses on recent research in this field, focuses on targeting the tumor itself and various pathways by which T cells kill tumor cells, including promoting apoptosis, reversing polarization TAMs, Inducing iron death in cancer cells, Remodeling the tumor microenvironment and reprogramming metabolism. Through analysis of recent research, it was found that these methods have their own advantages and can be combined to improve the therapeutic effect of drugs. However, the more basic mechanism is still a blank, and more exploration is needed.
Nanomedicine, Targeted Drug Delivery Systems, Cancer Therapy
1. Mengzhen C, Jing S, Zhongyang W. 2019 Chinese Jour. of Lumi 42 01 61-72
2. Wild C. World cancer report 2020. Imprimerie Faurite, France: World Health Organization 2020
3. Fang J, Nakamura H, Maeda H. 2021 Advanced drug delivery reviews 63 3 136-151
4. Choi J, Kim K, Mu J. 2022 J. Comm Jed Jour 20 19 1100-1106
5. Liu W. 2021. Hen Univ 2020.002107.
6. KOMOHARA Y, FUJIWARA Y, OHNISHIK, et al 2016 Adv Drug Deliv Rev 99 PtB 180-185
7. Chaohan W, Ziqiaoqiao D, Xiaoqiong Z et al. Chinese Med Rev 222 41 11 1595-1604
8. Li K. 2022.Chongqing Uni 001194
9. S. F. Viehmann, A. M. C. Böhner, C. Kurts, et al. 2018, Cellular Immu, 330 97~104
10. SUN K L. 2023 Huazhong Uni of sci and tech
11. Gao, X., Li, S., Ding, F., Liu, X., Wu, Y., Li, J., Zhang, C. 2021. Adv Mate, 33 9 , 2006116.
12. Yang L, Shi P, Zhao G, Xu J, Peng W, Zhang J, Zhang G, Wang X, Dong Z, Chen F, Cui H*. Sig Trans and Tard Ther. 2020, 5: p 8
13. Tian Yu G, Yong F, Yuanfei G et al. The Influ of the Chem in life 1-14 2023-09-1
14. FAN S H. 2023 Liaocheng University
15. Zhi Z, Jin-quan L, Chun-yu W, et al. 2023, Shanxi Med Jour 52 09 1268-1271
16. Stockwell, B R et al. 2017 Cell171 273–285
17. LI K. 2022 Chongqing University
18. Yufang Y Beiying D ang Yong Y. 2020, 26 18 216-223
19. Ye Ling, Zhang Huafeng Shiting L. 2019 J. Tumor meta and Nutr ele magazine 6 (4) 401-408.
20. SANG L J. 2023 Zhejiang University
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).